FIC20210017I1 - Kabotegraviiri tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti - Google Patents
Kabotegraviiri tai sen farmaseuttisesti hyväksyttävä suola tai solvaattiInfo
- Publication number
- FIC20210017I1 FIC20210017I1 FIC20210017C FIC20210017C FIC20210017I1 FI C20210017 I1 FIC20210017 I1 FI C20210017I1 FI C20210017 C FIC20210017 C FI C20210017C FI C20210017 C FIC20210017 C FI C20210017C FI C20210017 I1 FIC20210017 I1 FI C20210017I1
- Authority
- FI
- Finland
- Prior art keywords
- cabotegravir
- solvate
- pharmaceutically acceptable
- acceptable salt
- salt
- Prior art date
Links
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 title 1
- 229950005928 cabotegravir Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005131161 | 2005-04-28 | ||
| JP2005312076 | 2005-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FIC20210017I1 true FIC20210017I1 (fi) | 2021-06-10 |
Family
ID=37215098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIC20210017C FIC20210017I1 (fi) | 2005-04-28 | 2021-06-10 | Kabotegraviiri tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti |
Country Status (30)
| Country | Link |
|---|---|
| US (22) | US8129385B2 (enExample) |
| EP (9) | EP2527007B1 (enExample) |
| JP (2) | JP4295353B2 (enExample) |
| KR (4) | KR101848819B1 (enExample) |
| AU (1) | AU2006239177B8 (enExample) |
| BE (1) | BE2021C519I2 (enExample) |
| BR (1) | BRPI0610030B8 (enExample) |
| CA (1) | CA2606282C (enExample) |
| CY (7) | CY1115151T1 (enExample) |
| DK (6) | DK3187225T3 (enExample) |
| EA (1) | EA014162B1 (enExample) |
| ES (7) | ES2446324T3 (enExample) |
| FI (1) | FIC20210017I1 (enExample) |
| FR (1) | FR14C0041I2 (enExample) |
| HK (2) | HK1249742A1 (enExample) |
| HU (6) | HUE037795T2 (enExample) |
| IL (4) | IL186555A (enExample) |
| LT (5) | LT3045206T (enExample) |
| LU (2) | LU92446I2 (enExample) |
| MA (1) | MA29460B1 (enExample) |
| MX (2) | MX302718B (enExample) |
| NL (2) | NL300676I2 (enExample) |
| NO (5) | NO339525B1 (enExample) |
| NZ (1) | NZ562339A (enExample) |
| PL (5) | PL2465580T3 (enExample) |
| PT (5) | PT3045206T (enExample) |
| SI (6) | SI1874117T1 (enExample) |
| TW (1) | TWI378931B (enExample) |
| VN (1) | VN34404A1 (enExample) |
| WO (1) | WO2006116764A1 (enExample) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100582109C (zh) | 2003-12-24 | 2010-01-20 | 生物区科学管理控股有限公司 | 用于治疗呼吸道合胞体病毒感染的多环试剂 |
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US8129385B2 (en) | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| WO2006121831A2 (en) | 2005-05-10 | 2006-11-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
| JP5094725B2 (ja) | 2005-10-04 | 2012-12-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｈｉｖインテグラーゼ阻害剤 |
| AU2006307101A1 (en) * | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase |
| TWI423972B (zh) | 2006-09-28 | 2014-01-21 | Biota Scient Management | 治療呼吸系融合細胞病毒感染之多環劑 |
| RU2503679C2 (ru) | 2007-11-15 | 2014-01-10 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| SI2220076T1 (sl) | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| US8183372B2 (en) | 2008-07-25 | 2012-05-22 | Shionogi & Co., Ltd. | Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines |
| SG192550A1 (en) * | 2008-07-25 | 2013-08-30 | Viiv Healthcare Co | Chemical compounds |
| WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| ES2448766T3 (es) * | 2008-07-25 | 2014-03-17 | Viiv Healthcare Company | Profármacos de dolutegravir |
| WO2010011818A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| US8710249B2 (en) | 2008-12-11 | 2014-04-29 | Shionogi & Co., Ltd. | Maltol ether processes and intermediates |
| AU2014277831C1 (en) * | 2008-12-11 | 2022-10-06 | Shionogi & Co. Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| EP2376453B1 (en) | 2008-12-11 | 2019-11-20 | VIIV Healthcare Company | Intermediates for carbamoylpyridone hiv integrase inhibitors |
| EP2376080B1 (en) | 2008-12-11 | 2017-09-13 | Shionogi&Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| RS57244B1 (sr) | 2009-06-15 | 2018-07-31 | Shionogi & Co | Supstituisani policiklički derivati karbamoilpiridona |
| WO2011011483A1 (en) * | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
| ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
| EA032868B1 (ru) * | 2010-01-27 | 2019-07-31 | Вайв Хелткер Компани | Комбинация для лечения вич-инфекции |
| AU2014202405B2 (en) * | 2010-01-27 | 2016-02-25 | Viiv Healthcare Company | Antiviral therapy |
| AU2014202404C1 (en) * | 2010-01-27 | 2022-06-23 | Viiv Healthcare Company | Antiviral therapy |
| TWI508968B (zh) | 2010-02-08 | 2015-11-21 | Biota Scient Management | 用於治療呼吸道融合性病毒感染的化合物 |
| PH12012501689A1 (en) * | 2010-02-26 | 2012-11-05 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| RU2567385C2 (ru) | 2010-04-02 | 2015-11-10 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Макроциклические ингибиторы интегразы |
| US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
| US9073941B2 (en) | 2010-06-28 | 2015-07-07 | Academia Sinica | Compounds and methods for treating tuberculosis infection |
| ES2608377T3 (es) | 2010-08-05 | 2017-04-10 | Shionogi & Co., Ltd. | Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| CN103228653B (zh) * | 2010-09-24 | 2016-03-16 | 盐野义制药株式会社 | 被取代的多环性氨基甲酰基吡啶酮衍生物的前药 |
| US8796303B2 (en) | 2010-11-26 | 2014-08-05 | Biota Scientific Management Pty Ltd. | Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections |
| US20140213553A1 (en) * | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| EP2742051B1 (en) * | 2011-09-14 | 2016-10-12 | Mapi Pharma Limited | Amorpous form of the dolutegravir sodium salt |
| BR112014008896A2 (pt) * | 2011-10-12 | 2017-04-18 | Shionogi & Co | derivado de piridona policíclico tendo atividade inibidora de integrase |
| HRP20171665T1 (hr) | 2011-12-28 | 2017-12-15 | Global Blood Therapeutics, Inc. | Supstituirani spojevi benzaldehida i metode za njihovu primjenu u povećanju oksigenacije tkiva |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014099586A1 (en) * | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| MX344879B (es) * | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| RU2015131006A (ru) * | 2012-12-27 | 2017-01-30 | Джапан Тобакко Инк. | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) |
| EP2767272A1 (en) | 2013-02-18 | 2014-08-20 | Ratiopharm GmbH | Solid pharmaceutical dosage form of dolutegravir |
| WO2014125124A1 (en) | 2013-02-18 | 2014-08-21 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of dolutegravir |
| US9573965B2 (en) | 2013-02-19 | 2017-02-21 | Aurobindo Pharma Ltd | Process for the preparation of Dolutegravir |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2970308B1 (en) | 2013-03-15 | 2021-07-14 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| US9951079B2 (en) * | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| WO2015001572A2 (en) * | 2013-07-04 | 2015-01-08 | Hetero Research Foundation | Process for the preparation of intermediate of dolutegravir |
| LT3019503T (lt) | 2013-07-12 | 2017-11-27 | Gilead Sciences, Inc. | Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| WO2015009927A1 (en) | 2013-07-17 | 2015-01-22 | Ratiopharm Gmbh | Dolutegravir salts |
| WO2015019310A1 (en) | 2013-08-07 | 2015-02-12 | Mylan Laboratories Ltd | Process for the preparation of dolute-gravir and intermediates thereof |
| WO2015039348A1 (en) * | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| MX367057B (es) | 2013-09-27 | 2019-08-02 | Merck Sharp & Dohme | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih. |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| WO2015092752A1 (en) | 2013-12-20 | 2015-06-25 | Mylan Laboratories Ltd. | Novel crystalline form of dolutegravir sodium |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2015108945A2 (en) | 2014-01-14 | 2015-07-23 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| WO2015110897A2 (en) * | 2014-01-21 | 2015-07-30 | Laurus Labs Private Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| CN106866702B (zh) * | 2014-03-19 | 2019-03-19 | 杭州普晒医药科技有限公司 | 德罗格韦钠盐的晶型及其制备方法 |
| IN2014MU00916A (enExample) | 2014-03-20 | 2015-09-25 | Cipla Ltd | |
| WO2015177537A1 (en) * | 2014-05-20 | 2015-11-26 | Cipla Limited | Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof |
| NO2717902T3 (enExample) * | 2014-06-20 | 2018-06-23 | ||
| TWI744723B (zh) * | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| WO2016027879A1 (ja) * | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| WO2016092527A1 (en) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016102078A1 (en) | 2014-12-24 | 2016-06-30 | Ratiopharm Gmbh | Solid state forms of dolutegravir sodium |
| EP3045461A1 (en) | 2015-01-16 | 2016-07-20 | LEK Pharmaceuticals d.d. | Processes for preparing dolutegravir and analogues thereof |
| CN107531614B (zh) | 2015-02-06 | 2020-04-10 | 迈兰实验室有限公司 | 德罗格韦的制备方法 |
| CZ201599A3 (cs) | 2015-02-13 | 2016-08-24 | Zentiva, K.S. | Pevné formy solí dolutegraviru a způsob jejich přípravy |
| EP3285582B1 (en) * | 2015-03-26 | 2020-11-11 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| RU2712275C9 (ru) * | 2015-04-28 | 2020-03-19 | Сионоги Энд Ко., Лтд. | Замещенные полициклические производные пиридона и их пролекарства |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| CZ2015537A3 (cs) | 2015-08-04 | 2017-02-15 | Zentiva, K.S. | Pevné formy amorfního dolutegraviru |
| EP3337479B1 (en) | 2015-08-19 | 2023-12-13 | Laurus Labs Limited | Novel polymorphs of dolutegravir and salts thereof |
| KR102606625B1 (ko) | 2015-11-09 | 2023-11-27 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스의 치료를 위한 치료 조성물 |
| US10548910B2 (en) | 2015-11-17 | 2020-02-04 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors |
| DK3383392T3 (da) | 2015-12-04 | 2025-08-18 | Global Blood Therapeutics Inc | Doseringsskema for 2.HYDROXY.6.((2.(1.ISOPROPYL.1H.PYRAZOL.5.YL)PYRIDIN.3.YL)METHOXY)BENZALDEHYD |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| ES2742249T3 (es) | 2015-12-21 | 2020-02-13 | Lupin Ltd | Proceso para la preparación de inhibidores de la integrasa de VIH |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| WO2017208105A1 (en) | 2016-05-30 | 2017-12-07 | Lupin Limited | Novel crystalline form of dolutegravir sodium |
| WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| EP3496718A4 (en) | 2016-08-08 | 2020-01-22 | Hetero Labs Limited | ANTIRETROVIRAL COMPOSITIONS |
| US20190175511A1 (en) | 2016-08-08 | 2019-06-13 | Hetero Labs Limited | A Multi-Class Anti-Retroviral Composition |
| WO2018031987A1 (en) * | 2016-08-12 | 2018-02-15 | Nanjing Gator Meditech Company, Ltd. | Protein kinase regulators |
| WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| US20190216725A1 (en) * | 2016-09-21 | 2019-07-18 | Merck Shapr & Dohme Corp. | Drug delivery system for the delivery of integrase inhibitors |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| AU2017367714B2 (en) | 2016-12-02 | 2020-11-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| WO2018109786A1 (en) | 2016-12-16 | 2018-06-21 | Cipla Limited | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives |
| EP3573984A4 (en) | 2017-01-26 | 2020-07-29 | Merck Sharp & Dohme Corp. | USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS |
| EP3583107B1 (en) * | 2017-02-16 | 2020-11-18 | Sandoz AG | Crystalline form of cabotegravir sodium |
| EP3363802B1 (en) | 2017-02-16 | 2019-11-20 | Sandoz AG | Crystalline form of cabotegravir sodium |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | Combination drug therapy |
| KR20200031658A (ko) | 2017-07-21 | 2020-03-24 | 비이브 헬쓰케어 컴퍼니 | Hib 감염 및 aids를 치료하기 위한 요법 |
| EP3661940A1 (en) | 2017-09-07 | 2020-06-10 | Cipla Limited | New polymorphs of dolutegravir sodium |
| CN111386276B (zh) | 2017-10-06 | 2023-06-23 | 盐野义制药株式会社 | 制备取代的多环吡啶酮衍生物的立体选择性方法 |
| EP3737359A4 (en) | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM |
| WO2019159199A1 (en) | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
| US11458136B2 (en) | 2018-04-09 | 2022-10-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| SG11202011386QA (en) | 2018-05-31 | 2020-12-30 | Shionogi & Co | Polycyclic pyridone derivative |
| TWI880167B (zh) * | 2018-05-31 | 2025-04-11 | 日商鹽野義製藥股份有限公司 | 多環性吡啶并三衍生物 |
| AU2019277548B2 (en) | 2018-05-31 | 2023-12-14 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative |
| US11634431B2 (en) | 2018-07-12 | 2023-04-25 | Laurus Labs Limited | Process for purification of protected polycyclic carbamoylpyridone derivatives |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| MY207622A (en) | 2018-10-22 | 2025-03-06 | Univ Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN118873676A (zh) | 2018-11-29 | 2024-11-01 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| SI3938047T1 (sl) | 2019-03-22 | 2022-10-28 | Gilead Sciences, Inc. | Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
| JPWO2021107066A1 (enExample) | 2019-11-28 | 2021-06-03 | ||
| IL293566A (en) | 2019-12-09 | 2022-08-01 | Viiv Healthcare Co | Pharmaceutical preparations containing Cabotgravir |
| WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| WO2025068743A1 (en) | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| EP4208169A1 (en) | 2020-09-01 | 2023-07-12 | VIIV Healthcare Company | Combination of cabotegravir and levonorgestrel |
| KR20230079137A (ko) | 2020-09-30 | 2023-06-05 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도 |
| WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
| EP4255472A2 (en) | 2020-12-07 | 2023-10-11 | VIIV Healthcare Company | Combination therapy |
| PT4196479T (pt) | 2021-01-19 | 2024-01-03 | Gilead Sciences Inc | Compostos de piridotriazinas substituídos e suas utilizações |
| WO2022253294A1 (zh) | 2021-06-03 | 2022-12-08 | 江苏恒瑞医药股份有限公司 | 具有整合酶抑制活性的吡啶酮化合物及其药用用途 |
| CN114230579A (zh) * | 2021-11-12 | 2022-03-25 | 南京艾迪医药科技有限公司 | 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物 |
| JP2024542776A (ja) | 2021-12-03 | 2024-11-15 | ヴィーブ、ヘルスケア、カンパニー | （ｒ）－３－アミノブタン－１－オールの合成方法 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024153203A1 (en) * | 2023-01-18 | 2024-07-25 | Ascletis BioScience Co., Ltd | Integrase inhibitor and use thereof |
| WO2025068912A1 (en) | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical compositions |
| WO2025128496A1 (en) | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Crystalline form |
| WO2025128498A1 (en) | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| WO2025181723A1 (en) | 2024-03-01 | 2025-09-04 | ViiV Healthcare UK (No.3) Limited | Dosing regimen |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959316A (en) * | 1972-03-13 | 1976-05-25 | Snam Progetti S.P.A. | Procedure for propylene oxide synthesis |
| JPH0296506A (ja) | 1988-09-30 | 1990-04-09 | Daicel Chem Ind Ltd | 除草剤組成物 |
| JP2551472B2 (ja) | 1988-10-18 | 1996-11-06 | ダイセル化学工業株式会社 | ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤 |
| JP2533796B2 (ja) | 1988-10-18 | 1996-09-11 | ダイセル化学工業株式会社 | ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤 |
| US6093732A (en) | 1997-12-22 | 2000-07-25 | Pharmacia & Upjohn Company | 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents |
| EP1297834A4 (en) † | 2000-06-14 | 2007-05-09 | Shionogi & Co | ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS |
| US6580562B2 (en) | 2000-07-24 | 2003-06-17 | Yazaki Corporation | On-vehicle display unit |
| US6384263B1 (en) | 2000-08-04 | 2002-05-07 | E. I. Du Pont De Nemours And Company | Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane |
| DE60128936T2 (de) | 2000-10-12 | 2008-04-10 | Merck & Co, Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| JP2003032772A (ja) | 2001-07-12 | 2003-01-31 | Foster Electric Co Ltd | 耳掛け式イヤホン |
| WO2003016275A1 (fr) | 2001-08-10 | 2003-02-27 | Shionogi & Co., Ltd. | Agent antiviral |
| DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| EP1441735B1 (en) | 2001-10-26 | 2006-02-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| DE60315796T2 (de) | 2002-01-17 | 2008-06-05 | Merck & Co., Inc. | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| EP2045242A1 (en) | 2002-08-13 | 2009-04-08 | Shionogi&Co., Ltd. | Heterocyclic compounds having inhibitory activity against HIV integrase |
| AU2003267098B2 (en) * | 2002-09-11 | 2008-11-20 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
| AU2003292436B2 (en) | 2002-12-27 | 2009-07-30 | Msd Italia S.R.L. | Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors |
| US6960680B2 (en) | 2003-01-08 | 2005-11-01 | Rhodia Chirex, Inc. | Manufacture of water-soluble β-hydroxynitriles |
| JP2004244320A (ja) | 2003-02-10 | 2004-09-02 | Shionogi & Co Ltd | 含窒素複素環抗ウイルス剤 |
| JP2006528694A (ja) | 2003-05-13 | 2006-12-21 | スミスクライン ビーチャム コーポレーション | ナフチリジンインテグラーゼインヒビター |
| WO2005015927A1 (en) * | 2003-08-12 | 2005-02-17 | Rachel Beijer | Scheduled message service |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| JP4530642B2 (ja) | 2003-10-31 | 2010-08-25 | オリンパス株式会社 | 内視鏡装置 |
| AU2005211733A1 (en) | 2004-02-11 | 2005-08-25 | Shionogi & Co., Ltd | HIV integrase inhibitors |
| CA2557926A1 (en) | 2004-03-09 | 2005-09-22 | Monica Donghi | Hiv integrase inhibitors |
| AU2005227258A1 (en) | 2004-03-09 | 2005-10-06 | Merck & Co., Inc. | HIV integrase inhibitors |
| US7538112B2 (en) | 2004-05-07 | 2009-05-26 | Merck & Co., Inc. | HIV integrase inhibitors |
| WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| JP5317257B2 (ja) * | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体 |
| EP1866313A1 (en) * | 2005-03-31 | 2007-12-19 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
| US8129385B2 (en) * | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| JP2005312076A (ja) | 2005-05-26 | 2005-11-04 | Olympus Corp | 電子撮像装置 |
| EP1910363A4 (en) | 2005-08-04 | 2010-05-26 | Glaxosmithkline Llc | INHIBITORS OF HIV INTEGRASE |
| AU2006307101A1 (en) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase |
-
2006
- 2006-04-28 US US11/919,386 patent/US8129385B2/en active Active
- 2006-04-28 HU HUE16154531A patent/HUE037795T2/hu unknown
- 2006-04-28 DK DK17156762.1T patent/DK3187225T3/da active
- 2006-04-28 PT PT161545314T patent/PT3045206T/pt unknown
- 2006-04-28 VN VN201300151A patent/VN34404A1/vi unknown
- 2006-04-28 SI SI200631703T patent/SI1874117T1/sl unknown
- 2006-04-28 HU HUE18166621A patent/HUE056603T2/hu unknown
- 2006-04-28 SI SI200632344T patent/SI3284520T1/sl unknown
- 2006-04-28 DK DK16154531.4T patent/DK3045206T3/en active
- 2006-04-28 SI SI200632418T patent/SI3187225T1/sl unknown
- 2006-04-28 JP JP2008509227A patent/JP4295353B2/ja active Active
- 2006-04-28 KR KR1020157036007A patent/KR101848819B1/ko active Active
- 2006-04-28 ES ES12159082.2T patent/ES2446324T3/es active Active
- 2006-04-28 PL PL12159082T patent/PL2465580T3/pl unknown
- 2006-04-28 LT LTEP16154531.4T patent/LT3045206T/lt unknown
- 2006-04-28 EP EP12159079.8A patent/EP2527007B1/en active Active
- 2006-04-28 SI SI200631747T patent/SI2465580T1/sl unknown
- 2006-04-28 DK DK06758843.4T patent/DK1874117T3/da active
- 2006-04-28 PL PL17195280T patent/PL3284520T3/pl unknown
- 2006-04-28 EP EP17156762.1A patent/EP3187225B1/en not_active Not-in-force
- 2006-04-28 DK DK18166621.5T patent/DK3372281T3/da active
- 2006-04-28 WO PCT/US2006/016604 patent/WO2006116764A1/en not_active Ceased
- 2006-04-28 EP EP16154531.4A patent/EP3045206B2/en active Active
- 2006-04-28 PT PT67588434T patent/PT1874117E/pt unknown
- 2006-04-28 DK DK17195280.7T patent/DK3284520T3/da active
- 2006-04-28 EA EA200702080A patent/EA014162B1/ru active Protection Beyond IP Right Term
- 2006-04-28 KR KR1020147017235A patent/KR101580310B1/ko active Active
- 2006-04-28 LT LTEP18166621.5T patent/LT3372281T/lt unknown
- 2006-04-28 PL PL18166621T patent/PL3372281T3/pl unknown
- 2006-04-28 ES ES18166621T patent/ES2892304T3/es active Active
- 2006-04-28 SI SI200632410T patent/SI3372281T1/sl unknown
- 2006-04-28 ES ES17195280T patent/ES2743531T3/es active Active
- 2006-04-28 CA CA2606282A patent/CA2606282C/en active Active
- 2006-04-28 KR KR1020077027734A patent/KR101363875B1/ko active Active
- 2006-04-28 TW TW095115285A patent/TWI378931B/zh active
- 2006-04-28 PT PT17195280T patent/PT3284520T/pt unknown
- 2006-04-28 EP EP17195276.5A patent/EP3284519A1/en not_active Withdrawn
- 2006-04-28 ES ES12159079.8T patent/ES2567197T3/es active Active
- 2006-04-28 PT PT121590822T patent/PT2465580E/pt unknown
- 2006-04-28 EP EP06758843.4A patent/EP1874117B8/en active Active
- 2006-04-28 EP EP12159082.2A patent/EP2465580B1/en active Active
- 2006-04-28 BR BRPI0610030A patent/BRPI0610030B8/pt active IP Right Grant
- 2006-04-28 PL PL16154531T patent/PL3045206T3/pl unknown
- 2006-04-28 SI SI200632268T patent/SI3045206T1/en unknown
- 2006-04-28 EP EP18166621.5A patent/EP3372281B1/en active Active
- 2006-04-28 AU AU2006239177A patent/AU2006239177B8/en active Active
- 2006-04-28 ES ES16154531T patent/ES2667868T5/es active Active
- 2006-04-28 EP EP17195280.7A patent/EP3284520B1/en active Active
- 2006-04-28 NZ NZ562339A patent/NZ562339A/en unknown
- 2006-04-28 LT LTEP17195280.7T patent/LT3284520T/lt unknown
- 2006-04-28 DK DK12159082.2T patent/DK2465580T3/en active
- 2006-04-28 PL PL06758843T patent/PL1874117T3/pl unknown
- 2006-04-28 MX MX2007013351A patent/MX302718B/es active IP Right Grant
- 2006-04-28 HU HUE17195280 patent/HUE044978T2/hu unknown
- 2006-04-28 KR KR1020137028203A patent/KR101504998B1/ko active Active
- 2006-04-28 EP EP17156763.9A patent/EP3187226A1/en not_active Withdrawn
- 2006-04-28 PT PT181666215T patent/PT3372281T/pt unknown
- 2006-04-28 ES ES06758843.4T patent/ES2437268T3/es active Active
- 2006-04-28 ES ES17156762T patent/ES2906792T3/es active Active
-
2007
- 2007-10-10 NO NO20075165A patent/NO339525B1/no active Protection Beyond IP Right Term
- 2007-10-10 IL IL186555A patent/IL186555A/en active IP Right Grant
- 2007-10-25 MX MX2011010484A patent/MX312216B/es unknown
- 2007-11-20 MA MA30388A patent/MA29460B1/fr unknown
-
2008
- 2008-10-08 JP JP2008261344A patent/JP2009079058A/ja active Pending
-
2011
- 2011-10-23 IL IL215788A patent/IL215788A0/en unknown
-
2012
- 2012-01-18 US US13/352,686 patent/US8410103B2/en active Active
-
2013
- 2013-02-08 US US13/763,174 patent/US8778943B2/en active Active
- 2013-03-14 IL IL225207A patent/IL225207A/en active IP Right Review Request
- 2013-03-14 IL IL225206A patent/IL225206A/en active IP Right Grant
- 2013-11-27 CY CY20131101061T patent/CY1115151T1/el unknown
-
2014
- 2014-03-13 CY CY20141100201T patent/CY1116331T1/el unknown
- 2014-03-14 US US14/211,364 patent/US9051337B2/en active Active
- 2014-05-07 LU LU92446C patent/LU92446I2/xx unknown
- 2014-05-19 FR FR14C0041C patent/FR14C0041I2/fr active Active
- 2014-06-17 LT LTPA2014021C patent/LTC1874117I2/lt unknown
- 2014-06-25 CY CY2014024C patent/CY2014024I2/el unknown
- 2014-07-03 NL NL300676C patent/NL300676I2/nl unknown
- 2014-07-09 HU HUS1400039C patent/HUS1400039I1/hu unknown
-
2015
- 2015-04-30 US US14/700,679 patent/US9273065B2/en active Active
-
2016
- 2016-01-20 US US15/001,336 patent/US20160137666A1/en not_active Abandoned
- 2016-03-31 US US15/086,616 patent/US20160207939A1/en not_active Abandoned
- 2016-06-29 US US15/196,245 patent/US20160304535A1/en not_active Abandoned
- 2016-08-18 NO NO20161315A patent/NO340111B1/no active Protection Beyond IP Right Term
- 2016-10-11 US US15/290,094 patent/US20170029438A1/en not_active Abandoned
-
2017
- 2017-02-08 US US15/427,184 patent/US20170145033A1/en not_active Abandoned
- 2017-03-27 NO NO2017010C patent/NO2017010I2/no unknown
- 2017-04-10 US US15/482,896 patent/US20170209454A1/en not_active Abandoned
- 2017-04-27 US US15/498,667 patent/US20170224694A1/en not_active Abandoned
- 2017-04-27 US US15/498,684 patent/US20170224695A1/en not_active Abandoned
- 2017-05-17 US US15/597,343 patent/US20170253616A1/en not_active Abandoned
- 2017-05-18 US US15/598,671 patent/US20170267693A1/en not_active Abandoned
- 2017-05-18 US US15/598,655 patent/US20170260203A1/en not_active Abandoned
- 2017-09-07 US US15/697,847 patent/US20170369509A1/en not_active Abandoned
-
2018
- 2018-06-19 CY CY20181100633T patent/CY1120345T1/el unknown
- 2018-07-16 HK HK18109159.8A patent/HK1249742A1/en unknown
- 2018-08-16 HK HK18110519.1A patent/HK1251191A1/en unknown
-
2019
- 2019-01-10 US US16/244,441 patent/US20190152990A1/en not_active Abandoned
- 2019-05-01 US US16/400,373 patent/US10927129B2/en active Active
- 2019-08-20 CY CY20191100891T patent/CY1122052T1/el unknown
-
2020
- 2020-07-09 US US16/924,390 patent/US11267823B2/en active Active
-
2021
- 2021-05-10 NO NO2021018C patent/NO2021018I1/no unknown
- 2021-05-26 CY CY2021016C patent/CY2021016I2/el unknown
- 2021-06-03 BE BE2021C519C patent/BE2021C519I2/fr unknown
- 2021-06-08 NL NL301109C patent/NL301109I1/nl unknown
- 2021-06-10 FI FIC20210017C patent/FIC20210017I1/fi unknown
- 2021-06-14 HU HUS2100023C patent/HUS2100023I1/hu unknown
- 2021-06-14 HU HUS2100022C patent/HUS2100022I1/hu unknown
- 2021-06-15 LU LU00210C patent/LUC00210I2/en unknown
- 2021-06-16 LT LTPA2021512C patent/LTC2465580I2/lt unknown
- 2021-10-06 CY CY20211100866T patent/CY1124601T1/el unknown
-
2022
- 2022-01-27 US US17/586,006 patent/US20220213121A1/en not_active Abandoned
-
2023
- 2023-11-08 NO NO2023042C patent/NO2023042I1/no unknown
-
2024
- 2024-04-09 US US18/630,561 patent/US20240279238A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20210017I1 (fi) | Kabotegraviiri tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti | |
| FIC20240007I1 (fi) | Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola | |
| FIC20230039I1 (fi) | Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola | |
| NO2022057I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| FIC20240041I1 (fi) | Aprositentaani tai sen farmaseuttisesti hyväksyttävä suola | |
| FIC20240046I1 (fi) | Vibegroni tai sen farmaseuttisesti hyväksyttävä suola | |
| FIC20253002I1 (fi) | Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola | |
| FIC20150052I1 (fi) | Kobisistaatti tai sen farmaseuttisesti hyväksyttävä suola | |
| NL301106I1 (nl) | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan | |
| FIC20200039I1 (fi) | Kefiderokoli valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa | |
| FIC20210010I1 (fi) | Fedratinibi tai sen farmaseuttisesti hyväksyttävä suola tai sen farmaseuttisesti hyväksyttävä hydraatti, erityisesti fedratinibidihydrokloridimonohydraatti | |
| FIC20230033I1 (fi) | Piflufolastaatti (18F) tai sen farmaseuttisesti hyväksyttävä suola | |
| FIC20190029I1 (fi) | Brigatinibi tai sen farmaseuttisesti hyväksyttävä suola | |
| FIC20220043I1 (fi) | Difelikefaliini, valinnaisesti farmaseuttisesti hyväksyttävänä suolana, hydraattina, solvaattina, happosuolahydraattina tai N-oksidina | |
| NL301003I2 (nl) | Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300993I2 (nl) | Apalutamide of een farmaceutisch aanvaardbaar zout daarvan | |
| HUS000502I2 (hu) | Opikapon vagy egy gyógyászatilag elfogadható sója | |
| NL300865I2 (nl) | Eluxadoline of een farmaceutisch aanvaardbaar zout ervan | |
| FIC20150014I1 (fi) | Fluralaneeri tai sen suola | |
| DE602006018355D1 (de) | Transdermale verabreichung eines meptazinolsalzes | |
| IS8578A (is) | 3- karbamoýl - 2- pýridón afleiður | |
| DK1725553T3 (da) | Tetrahydropyridoindolderivater | |
| DE602006003575D1 (de) | Schwenkzylinder | |
| ATE540935T1 (de) | Chinazolinderivate | |
| DK1761541T3 (da) | Pyrrazolo-pyrimidin-derivater |